Step 1 topics → General Pharmacology → Digoxin Toxicity

Digoxin Toxicity

USMLE Step 1 trap: Misses that hypokalemia (e.g., from diuretics) dramatically increases digoxin toxicity by enhancing its binding to Na+/K+-ATPase. Hypokalemia potentiates digoxin toxicity because K+ and digoxin compete for the same binding site on Na+/K+-ATPase; low K+ increases digoxin binding and toxicity.

Digoxin toxicity is one of those topics where USMLE Step 1 rewards students who understand the mechanism, not just the drug. Digoxin inhibits Na+/K+-ATPase, increasing intracellular Na+, which reduces Ca2+ extrusion via the Na+/Ca2+ exchanger — net result is increased intracellular Ca2+ and stronger cardiac contractions. Toxicity breaks that balance and produces a recognizable clinical picture spanning GI, neurological, visual, and cardiac systems. The exam tests this from two main angles: recognizing the toxic presentation (especially the classic but often-missed visual findings), and knowing when and why to use digoxin-specific Fab fragments.

What makes this topic tricky is that students often treat digoxin toxicity as a static drug effect, ignoring the variables that amplify it. Hypokalemia is the biggest one — diuretic-treated heart failure patients are at double risk, and the exam loves to bury this in a clinical vignette. The visual changes are another classic trap: students default to 'blurry vision' when the actual answer is yellow-green xanthopsia and halos, a direct result of digoxin's effect on retinal cones. These aren't trivia points — they're the clinical discriminators the exam uses to distinguish students who understand the mechanism from those who memorized the drug name.

There's also a critical management pitfall: IV calcium, which you'd normally reach for in hyperkalemic cardiac emergencies, is contraindicated here. Digoxin toxicity causes intracellular calcium overload, and adding IV calcium can precipitate fatal ventricular arrhythmias — the so-called 'stone heart.' USMLE Step 1 will put you in exactly that scenario to see if you know the exception. Digoxin-Fab (Digibind) is the antidote, and you need to know the specific indications that trigger its use.

From real student decks
3%have cards covering this topic
0%have mature cards
2median lapses in 14 days

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: Digoxin toxicity risk is independent of serum potassium levels.
Right: Hypokalemia potentiates digoxin toxicity because K+ and digoxin compete for the same binding site on Na+/K+-ATPase; low K+ increases digoxin binding and toxicity.
Digoxin and K+ compete for the same binding site on Na+/K+-ATPase — when serum K+ is low, digoxin wins that competition more easily and binds more avidly to the pump. This means a patient on a loop or thiazide diuretic who develops hypokalemia can become toxic at a 'therapeutic' digoxin level. Always check electrolytes when evaluating digoxin toxicity, and recognize that the combination of diuretic use + digoxin is a red flag setup in any vignette.
Common mistake
Gap: Unaware that IV calcium is contraindicated in digoxin toxicity despite being used for other hyperkalemia-related cardiac emergencies
IV calcium is contraindicated in digoxin toxicity because it can precipitate fatal ventricular arrhythmias ('stone heart') by worsening intracellular calcium overload.
Digoxin toxicity works by flooding cardiac cells with intracellular calcium. Giving IV calcium in this context dumps even more calcium into an already overloaded system, risking a sustained tetanic cardiac contraction — 'stone heart' — that is uniformly fatal. This is a critical exception to memorize: IV calcium is your go-to for hyperkalemia-induced cardiac toxicity in most settings, but digoxin toxicity is the one scenario where it is absolutely contraindicated.
Common mistake
Wrong: Visual disturbances in digoxin toxicity are nonspecific blurring.
Right: Digoxin toxicity classically causes yellow-green color vision changes (xanthopsia) and halos around lights, reflecting its effect on retinal cone cells.
The visual toxicity of digoxin is mechanistically specific: it affects retinal cone cells, producing xanthopsia (yellow-green tinting of vision) and the perception of halos around lights. This is not generic blurring — it's a distinctive, pathognomonic finding. When a stem describes a patient on digoxin seeing yellow halos or describing a yellowish tint to their vision, that's the exam signaling toxicity. Nonspecific blurring would not point you toward digoxin.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the full clinical presentation of digoxin toxicity: nausea/vomiting/anorexia (GI), yellow-green color vision changes and halos around lights (visual), confusion and fatigue (neuro), and AV block or ventricular arrhythmias on ECG.
  2. Know the indications for digoxin-specific Fab fragments (Digibind): life-threatening arrhythmias, hemodynamic instability, severe hyperkalemia (K+ >5.5 in acute toxicity), and ingestion of a known lethal dose.

Can you avoid these mistakes?

A 72-year-old man with heart failure on digoxin and furosemide presents with nausea, confusion, and seeing yellow halos around lights. His ECG shows a 2nd-degree AV block. His K+ is 3.0 mEq/L. Why is his potassium relevant to his digoxin toxicity, and what is the next best step in management?
A patient with known digoxin toxicity has a serum K+ of 6.2 mEq/L and is showing signs of hemodynamic instability. A nurse asks if you want to give IV calcium gluconate as you would for other cases of severe hyperkalemia. What is your response and why?
Which of the following is most consistent with digoxin toxicity: (A) tunnel vision and scotomas, (B) yellow-green color changes and halos around lights, (C) painless loss of central vision, (D) bilateral temporal hemianopia?
A patient on digoxin for atrial fibrillation develops symptomatic bradycardia with a ventricular rate of 32 bpm and a blood pressure of 80/50. What are the indications for giving digoxin-specific Fab fragments, and does this patient meet them?

Related topics

ADME and Bioavailability Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination

See how your Anki deck covers this topic.

Upload your deck for a free audit →